May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...
October 12, 2012 (Montreal, Quebec) — In a finding described as both surprising and practice-changing, octreotide (Sandostatin, Novartis) showed no benefit over less expensive, more accessible ...
Israeli drugmaker Teva Pharmaceuticals (NYSE:TEVA) announced Tuesday the market launch of the first and only U.S. generic for Sandostatin LAR, an antidiarrheal medication marketed by Swiss ...
Basel, June 3, 2021 — Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 ...
Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance) A total of 139 patients were ...
Please provide your email address to receive an email when new articles are posted on . The addition of a radioligand therapy to first-line treatment with long-acting octreotide prolonged PFS for ...
Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced the launch of a generic form of Sandostatin LAR Depot. The medication is ...
ZURICH, May 28 (Reuters) - Swiss drugmaker Novartis AG said late stage data showed its Sandostatin LAR drug helped fight tumuors of the mid-gut, while other drugs showed benefits for treating advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results